Overview

Durvalumab and Oleclumab in Resectable PDAC

Status:
Recruiting

Trial end date:
2026-10-30

Target enrollment:

Participant gender:

Summary

This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.

Phase:

Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Treatments:

Durvalumab